Sarepta Therapeutics Off To A Strong Start With New Name And Data
This article was originally published in The Pink Sheet Daily
Executive Summary
The RNA drug-discovery company, formerly AVI BioPharma, is reinventing itself as an orphan disease drug specialist called Sarepta Therapeutics. With the release of positive Phase IIb data on its lead candidate for Duchenne muscular dystrophy, the transformation has gotten a big boost.
You may also be interested in...
Financings Of The Fortnight: Life Science Venture Funding Not Necessarily On The Decline
Plus news on recent financings by Foundation Medicine, Ultragenyx, Labrys Biologics, Solstice Biologics and Sarepta Therapeutics.
$118 Million Offering Should Position Sarepta Strongly For Partnering Talks
As the Duchenne muscular dystrophy-focused biotech raises significant cash from institutional investors, CEO clarifies that Sarepta is intent on finding the right partner, structure and economics for an ex-North American opportunity.
GlaxoSmithKline in a Rare-Disease Pact with Prosensa for RNA-modulation Drugs
GSK is paying £16m ($25m) upfront for rights to Prosensa's lead Duchenne's compound, and takes hallmark options to related candidates.